Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply

被引：0
作者：
Yamamoto, T. [1 ]
Shimoyama, T. [1 ]
Umegae, S. [1 ]
Matsumoto, K. [1 ]
机构：
[1] Yokkaichi Hazu Med Ctr, Ctr Inflammatory Bowel Dis, Yokaichi, Mie, Japan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2016年 / 43卷 / 11期
关键词：
FK506;
D O I：
10.1111/apt.13602
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1243 / 1243
页数：1
相关论文
共 5 条
[1]   Letter: which patient profile for tacrolimus in ulcerative colitis? [J].
Laharie, D. ;
Poullenot, F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (11) :1242-1243
[2]   A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis [J].
Ogata, H. ;
Matsui, T. ;
Nakamura, M. ;
Iida, M. ;
Takazoe, M. ;
Suzuki, Y. ;
Hibi, T. .
GUT, 2006, 55 (09) :1255-1262
[3]   Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis [J].
Ogata, Haruhiko ;
Kato, Jun ;
Hirai, Fumihito ;
Hida, Nobuyuki ;
Matsui, Toshiyuki ;
Matsumoto, Takayuki ;
Koyanagi, Katsuyoshi ;
Hibi, Toshifumi .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (05) :803-808
[4]   5-AMINOSALICYLIC ACID ENEMA IN THE TREATMENT OF DISTAL ULCERATIVE-COLITIS, PROCTOSIGMOIDITIS, AND PROCTITIS [J].
SUTHERLAND, LR ;
MARTIN, F ;
GREER, S ;
ROBINSON, M ;
GREENBERGER, N ;
SAIBIL, F ;
MARTIN, T ;
SPARR, J ;
PROKIPCHUK, E ;
BORGEN, L .
GASTROENTEROLOGY, 1987, 92 (06) :1894-1898
[5]   Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study [J].
Yamamoto, T. ;
Shimoyama, T. ;
Umegae, S. ;
Matsumoto, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (06) :705-716
1